164 related articles for article (PubMed ID: 37345085)
41. Predictive and Prognostic Brain Metastases Assessment in Luminal Breast Cancer Patients: FN14 and GRP94 from Diagnosis to Prophylaxis.
Martínez-Aranda A; Hernández V; Moreno F; Baixeras N; Cuadras D; Urruticoechea A; Gil-Gil M; Vidal N; Andreu X; Seguí MA; Ballester R; Castella E; Sierra A
Front Oncol; 2017; 7():283. PubMed ID: 29250484
[TBL] [Abstract][Full Text] [Related]
42. Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets.
Varešlija D; Priedigkeit N; Fagan A; Purcell S; Cosgrove N; O'Halloran PJ; Ward E; Cocchiglia S; Hartmaier R; Castro CA; Zhu L; Tseng GC; Lucas PC; Puhalla SL; Brufsky AM; Hamilton RL; Mathew A; Leone JP; Basudan A; Hudson L; Dwyer R; Das S; O'Connor DP; Buckley PG; Farrell M; Hill ADK; Oesterreich S; Lee AV; Young LS
J Natl Cancer Inst; 2019 Apr; 111(4):388-398. PubMed ID: 29961873
[TBL] [Abstract][Full Text] [Related]
43. Does androgen receptor have a prognostic role in patients with estrogen/progesterone-negative and c-erbB-2-positive breast cancer?
Arslan C; Isik M; Guler G; Kulac I; Solak M; Turker B; Ozisik Y; Altundag K
Am Surg; 2012 Sep; 78(9):992-9. PubMed ID: 22964210
[TBL] [Abstract][Full Text] [Related]
44. Association between Lymph Node Status and Expression Levels of Androgen Receptor, miR-185, miR-205, and miR-21 in Breast Cancer Subtypes.
Kalinina TS; Kononchuk VV; Yakovleva AK; Alekseenok EY; Sidorov SV; Gulyaeva LF
Int J Breast Cancer; 2020; 2020():3259393. PubMed ID: 32373367
[TBL] [Abstract][Full Text] [Related]
45. The Androgen Receptor Promotes Cellular Proliferation by Suppression of G-Protein Coupled Estrogen Receptor Signaling in Triple-Negative Breast Cancer.
Shen Y; Yang F; Zhang W; Song W; Liu Y; Guan X
Cell Physiol Biochem; 2017; 43(5):2047-2061. PubMed ID: 29059676
[TBL] [Abstract][Full Text] [Related]
46. Androgen Receptor Immunohistochemistry as a Companion Diagnostic Approach to Predict Clinical Response to Enzalutamide in Triple-Negative Breast Cancer.
Kumar V; Yu J; Phan V; Tudor IC; Peterson A; Uppal H
JCO Precis Oncol; 2017 Nov; 1():1-19. PubMed ID: 35172518
[TBL] [Abstract][Full Text] [Related]
47. Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?
Safarpour D; Pakneshan S; Tavassoli FA
Am J Cancer Res; 2014; 4(4):353-68. PubMed ID: 25057438
[TBL] [Abstract][Full Text] [Related]
48. Ceritinib is a novel triple negative breast cancer therapeutic agent.
Dong S; Yousefi H; Savage IV; Okpechi SC; Wright MK; Matossian MD; Collins-Burow BM; Burow ME; Alahari SK
Mol Cancer; 2022 Jun; 21(1):138. PubMed ID: 35768871
[TBL] [Abstract][Full Text] [Related]
49. Androgen receptor status is highly conserved during tumor progression of breast cancer.
Grogg A; Trippel M; Pfaltz K; Lädrach C; Droeser RA; Cihoric N; Salhia B; Zweifel M; Tapia C
BMC Cancer; 2015 Nov; 15():872. PubMed ID: 26552477
[TBL] [Abstract][Full Text] [Related]
50. Androgen receptor expression and prognosis in Hispanic/Latino women with triple negative breast cancer.
Melo-Uribe MA; Serrano-Gómez SJ; Abaunza Chagin MC
Rev Esp Patol; 2022; 55(2):96-104. PubMed ID: 35483775
[TBL] [Abstract][Full Text] [Related]
51. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers.
Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW; Lee KS
Ann Oncol; 2011 Aug; 22(8):1755-62. PubMed ID: 21310761
[TBL] [Abstract][Full Text] [Related]
52. Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry.
Laakmann E; Witzel I; Neunhöffer T; Park-Simon TW; Weide R; Riecke K; Polasik A; Schmidt M; Puppe J; Mundhenke C; Lübbe K; Hesse T; Thill M; Zahm DM; Denkert C; Fehm T; Nekljudova V; Rey J; Loibl S; Müller V
ESMO Open; 2022 Jun; 7(3):100495. PubMed ID: 35653983
[TBL] [Abstract][Full Text] [Related]
53. HC-1119, a deuterated Enzalutamide, inhibits Migration, Invasion and Metastasis of the AR-positive triple-negative breast Cancer cells.
Wu X; Feng W; Yang M; Liu X; Gao M; Li X; Gan L; He T
Mol Biol Rep; 2022 Oct; 49(10):9231-9240. PubMed ID: 35960413
[TBL] [Abstract][Full Text] [Related]
54. Clinico-pathological relationship between androgen receptor and tumour infiltrating lymphocytes in triple negative breast cancer.
Elghazawy H; Bakkach J; Helal T; Aref AM; Kelany M; Abdallah LE; Abdelbakey FS; Ali D; Ali DZ; Ahmed MO; El-Hafeez AAA; Ghosh P; Alorabi MO
Ecancermedicalscience; 2021; 15():1317. PubMed ID: 35047068
[TBL] [Abstract][Full Text] [Related]
55. Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study.
Bhattarai S; Klimov S; Mittal K; Krishnamurti U; Li XB; Oprea-Ilies G; Wetherilt CS; Riaz A; Aleskandarany MA; Green AR; Ellis IO; Cantuaria G; Gupta M; Manne U; Agboola J; Baskovich B; Janssen EAM; Callagy G; Walsh EM; Mehta A; Dogra A; Shet T; Gajaria P; Traina T; Nggada HA; Omonisi A; Ahmed SA; Rakha EA; Rida P; Aneja R
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31319547
[TBL] [Abstract][Full Text] [Related]
56. MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression.
Christenson JL; Butterfield KT; Spoelstra NS; Norris JD; Josan JS; Pollock JA; McDonnell DP; Katzenellenbogen BS; Katzenellenbogen JA; Richer JK
Horm Cancer; 2017 Apr; 8(2):69-77. PubMed ID: 28194662
[TBL] [Abstract][Full Text] [Related]
57. The prognostic value of androgen receptor (AR) in HER2-enriched metastatic breast cancer.
Wang X; Bi X; Huang Z; Huang J; Xia W; Shi W; Yuan Z
Endocr Relat Cancer; 2020 Apr; 27(4):199-208. PubMed ID: 31958314
[TBL] [Abstract][Full Text] [Related]
58. The prognostic analysis of clinical breast cancer subtypes among patients with liver metastases from breast cancer.
Duan XF; Dong NN; Zhang T; Li Q
Int J Clin Oncol; 2013 Feb; 18(1):26-32. PubMed ID: 22041927
[TBL] [Abstract][Full Text] [Related]
59. Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases?
Bronte G; Bravaccini S; Ravaioli S; Puccetti M; Scarpi E; Andreis D; Tumedei MM; Sarti S; Cecconetto L; Pietri E; De Simone V; Maltoni R; Bonafè M; Amadori D; Rocca A
Transl Oncol; 2018 Aug; 11(4):950-956. PubMed ID: 29890379
[TBL] [Abstract][Full Text] [Related]
60. Association of androgen receptor and tumour-infiltrating lymphocytes with bone recurrence in triple-negative breast cancer.
Ilenič P; Herman A; Langerholc E; Gazić B; Šeruga B
J Bone Oncol; 2024 Feb; 44():100518. PubMed ID: 38374890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
